8-K: Beta Bionics Raises Guidance on Strong Q3 2025 Results

Beta Bionics reported strong third-quarter 2025 financial results, including a 63% increase in net sales, and subsequently raised its full-year 2025 guidance.

Summary

• Net sales for Q3 2025 reached $27.3 million, marking a 63% increase compared to $16.7 million in Q3 2024.
• Durable Medical Equipment (DME) channel net sales grew 45% to $21.0 million, up from $14.5 million in Q3 2024.
• Pharmacy Benefit Plan (PBP) channel net sales surged 178% to $6.2 million, compared to $2.2 million in Q3 2024.
• Gross margin improved to 55.5%, an increase of 212 basis points from 53.4% in Q3 2024.
• The installed customer base expanded by 162% to 29,419 users, up from 11,214 in Q3 2024.
• New patient starts totaled 5,334, a 68% increase over 3,180 in Q3 2024.
• 70% of new patient starts originated from multiple daily injections (MDI) users.
• A low 30s percentage of new patient starts were reimbursed through the PBP channel.
• Loss from operations was $17.0 million, or negative 63% of sales, compared to $11.0 million (negative 66% of sales) in Q3 2024.
• Net loss was $14.2 million, or negative 52% of sales, compared to $9.7 million (negative 58% of sales) in Q3 2024.
• Adjusted EBITDA was negative $12.2 million, or negative 45% of sales, an improvement from negative $8.7 million (negative 52% of sales) in Q3 2024.
• Cash, cash equivalents, short-term investments, and long-term investments stood at $274.0 million as of September 30, 2025.
• Full year 2025 total revenue guidance was raised to greater than $96.5 million (previously $88 million to $93 million).
• Full year 2025 guidance for new patient starts reimbursed through the PBP channel was raised to 27% to 29% (previously 25% to 28%).
• Full year 2025 gross margin guidance was raised to 54% to 55% (previously 52% to 55%).
• Effective formulary agreements are in place with all major pharmacy benefit managers (PBMs) in the U.S. as of July 1, 2025.
• The glucagon pharmacokinetic (PK)-pharmacodynamic (PD) trial in Canada was completed in September 2025, with results in-line with management expectations.
• Special 510(k) clearance for iLet feature updates, including a more seamless cartridge change process and elimination of redundant low glucose alerts, was received on September 29, 2025.

Sentiment

Score: 8

Explanation: The company demonstrated strong growth in net sales and customer acquisition, significantly improved gross margin, and raised its full-year guidance across key metrics. Strategic achievements in PBM coverage and bihormonal system development are positive indicators. While still operating at a loss, the improved efficiency and substantial cash reserves provide a strong foundation for continued growth and innovation.

Positives

• Net sales increased significantly by 63% year-over-year to $27.3 million in Q3 2025.
• Both DME and PBP channels showed strong growth, with PBP channel sales up 178% year-over-year.
• Gross margin improved by 212 basis points to 55.5% in Q3 2025.
• The installed customer base grew substantially by 162% year-over-year to 29,419 users.
• New patient starts increased by 68% year-over-year to 5,334.
• Full year 2025 guidance was raised across total revenue, PBP channel new patient starts, and gross margin, indicating strong future expectations.
• Achieved effective formulary agreements with all major PBMs in the U.S., enhancing market access and reducing patient/plan upfront costs.
• Completed the glucagon PK-PD trial with results aligning with expectations, supporting the development of a bihormonal system.
• Received Special 510(k) clearance for iLet feature updates, improving user experience.
• Operating loss, net loss, and Adjusted EBITDA as a percentage of sales all improved year-over-year, indicating better operational efficiency.
• Maintained a strong cash position with $274.0 million in cash, cash equivalents, and investments.

Negatives

• The company continues to report an operating loss of $17.0 million in Q3 2025.
• A net loss of $14.2 million was recorded for Q3 2025.
• Adjusted EBITDA remained negative at $12.2 million in Q3 2025.

Risks

• Risks inherent in developing product candidates.
• Uncertainty regarding future results from ongoing and future studies and clinical trials.
• Ability to obtain adequate financing to fund product development and other expenses.
• Risk that real-world data or future results may not be consistent with interim, initial, or preliminary results from prior studies.
• Trends in the industry may impact performance.
• Relationships with existing and future collaboration partners are crucial.
• The legal and regulatory framework for the industry could change.
• Future expenditures may be higher than anticipated.
• Potential impacts of global macroeconomic conditions on business operations.

Future Outlook

Beta Bionics raised its full year 2025 guidance, now estimating total revenue of greater than $96.5 million, 27% to 29% of new patient starts reimbursed through the PBP channel, and a gross margin of 54% to 55%. The company expects to initiate a feasibility trial in New Zealand in the fourth quarter of 2025 to test its bihormonal system, including the pump and dosing algorithms, in humans for the first time with the new glucagon asset.

Management Comments

• Full glucagon PK/PD results are in-line with management expectations and are believed to be supportive of the continued development of the glucagon asset for use in the bihormonal system in development.

Industry Context

Beta Bionics operates in the rapidly evolving diabetes management solutions sector, focusing on advanced adaptive closed-loop algorithms for insulin delivery. The company's success in securing formulary agreements with major PBMs aligns with a broader industry trend towards increasing patient access and reducing out-of-pocket costs for innovative medical devices through pharmacy benefits. The ongoing development of a bihormonal system, incorporating glucagon, positions Beta Bionics at the forefront of next-generation diabetes technology, aiming to provide more comprehensive and autonomous glycemic control compared to existing insulin-only automated insulin delivery systems.

Stakeholder Impact

• Shareholders: Positive financial results and raised guidance are likely to increase investor confidence and potentially lead to share price appreciation.
• Customers (Patients): Improved user experience through iLet feature updates and expanded access via PBM formulary agreements enhance product utility and affordability. The development of a bihormonal system promises more advanced treatment options.
• Employees: Strong company growth and ongoing product development suggest job stability and potential for expansion and career opportunities.
• PBMs/Health Plans: Successful formulary agreements indicate strong partnerships and integration into healthcare systems, potentially leading to broader adoption of the iLet system.

Next Steps

• Actively work with health plans that partner with PBMs to drive coverage of iLet under their pharmacy benefit.
• Initiate a feasibility trial in New Zealand in the fourth quarter of 2025 to test the bihormonal system, including the pump and dosing algorithms, in humans for the first time with the new glucagon asset.
• Continue the development of the glucagon asset for use in the bihormonal system.

Key Dates

Recommendation

Beta Bionics delivered exceptional Q3 2025 results, marked by a 63% year-over-year increase in net sales and a 162% surge in its installed customer base. The company's decision to raise its full-year 2025 guidance for revenue, PBP channel penetration, and gross margin signals robust operational momentum and a positive outlook. Strategic milestones, including securing formulary agreements with all major PBMs and advancing its bihormonal system development, significantly strengthen its market position and long-term growth potential. Despite current operating losses, the strong growth trajectory, improving efficiency, and substantial cash reserves make this an attractive investment for seasoned investors.

Keywords

Diabetes Management, Medical Device, Insulin Delivery, Bionic Pancreas, iLet, Q3 Earnings, Financial Results, Guidance Update, Healthcare Technology, SEC Filing